Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept; Methotrexate

Criteria

Inclusion Criteria:

• Active plaque psoriasis involving >10% body surface area and/or minimal screening PASI score 8.

• Methotrexate >7.5 mg/week for the last 3 months

Exclusion Criteria:

• Predominantly guttate, erythrodermic or pustular psoriasis

• Other skin conditions than psoriasis